PMID: 7543139Aug 1, 1995Paper

CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation

The Journal of Experimental Medicine
M F Krummel, J P Allison

Abstract

The importance of the B7/CD28/CTLA-4 molecules has been established in studies of antigen-presenting cell-derived B7 and its interaction with the T cell costimulatory molecule CD28. CTLA-4, a T cell surface glycoprotein that is related to CD28, can also interact with B7-1 and B7-2. However, less is known about the function of CTLA-4, which is expressed at highest levels after activation. We have generated an antibody to CTLA-4 to investigate the consequences of engagement of this molecule in a carefully defined system using highly purified T cells. We show here that the presence of low levels of B7-2 on freshly explanted T cells can partially inhibit T cell proliferation, and this inhibition is mediated by interactions with CTLA-4. Cross-linking of CTLA-4 together with the TCR and CD28 strongly inhibits proliferation and IL-2 secretion by T cells. Finally, results show that CD28 and CTLA-4 deliver opposing signals that appear to be integrated by the T cell in determining the response to activation. These data strongly suggest that the outcome of T cell antigen receptor stimulation is regulated by CD28 costimulatory signals, as well as inhibitory signals derived from CTLA-4.

References

Dec 1, 1992·The Journal of Experimental Medicine·P S LinsleyN K Damle
Jan 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·H ReiserL M Nadler
May 1, 1992·Proceedings of the National Academy of Sciences of the United States of America·Z Razi-WolfH Reiser
Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·C D GimmiL M Nadler
Sep 1, 1991·The Journal of Experimental Medicine·P S LinsleyJ A Ledbetter
Jul 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·P S LinsleyJ A Ledbetter
Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·W L HavranJ P Allison
Jul 16, 1987·Nature·J F BrunetP Golstein
Dec 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·D J LenschowJ A Bluestone
Mar 1, 1994·The Journal of Experimental Medicine·K E TruittJ B Imboden
Jul 1, 1994·Immunology Today·C H JuneC B Thompson
Sep 27, 1994·Proceedings of the National Academy of Sciences of the United States of America·A AugustB Dupont
Sep 1, 1994·Immunity·M K Jenkins
Sep 1, 1994·Immunity·J M GreenC B Thompson
Mar 12, 1993·Cell·Z SongyangR J Lechleider
Nov 4, 1993·Nature·M AzumaC Somoza
Jan 1, 1995·The Journal of Experimental Medicine·H SchneiderC E Rudd
Aug 1, 1994·Immunity·T L WalunasJ A Bluestone
May 1, 1994·International Immunology·A August, B Dupont
Mar 29, 1994·Proceedings of the National Academy of Sciences of the United States of America·K V PrasadC E Rudd
Jan 1, 1993·Annual Review of Immunology·P S Linsley, J A Ledbetter

❮ Previous
Next ❯

Citations

Nov 15, 1996·International Journal of Cancer. Journal International Du Cancer·R Kammerer, S von Kleist
Apr 29, 1998·European Journal of Immunology·R Hakamada-TaguchiH Nariuchi
Nov 10, 1998·European Journal of Immunology·C A ChambersJ P Allison
Nov 11, 1999·European Journal of Immunology·G MagistrelliY Delneste
Jul 13, 2001·European Journal of Immunology·H SchneiderC E Rudd
Mar 1, 2000·Biochemical and Biophysical Research Communications·H Schneider, C E Rudd
Sep 1, 1996·Cancer Metastasis Reviews·P F Searle, L S Young
Jun 22, 1999·Immunologic Research·J M SlavikB E Bierer
Sep 1, 1999·Immunologic Research·W C GauseJ F Urban
Jun 15, 1999·Molecular Biotechnology·D C Kilpatrick
Jan 1, 1996·Immunologic Research·C Dubey, M Croft
Apr 23, 2005·Cancer Immunology, Immunotherapy : CII·Michael S SabelRichard B Bankert
Feb 10, 2009·Cancer Immunology, Immunotherapy : CII·Jeffrey Weber
Apr 6, 2011·Cancer Immunology, Immunotherapy : CII·Jianda YuanJedd D Wolchok
Aug 23, 2011·Cancer Immunology, Immunotherapy : CII·Eleni-Kyriaki VetsikaDimitris Mavroudis
Jul 23, 2013·Cancer Immunology, Immunotherapy : CII·Maria Jure-KunkelRachel Humphrey
May 19, 2009·Rheumatology International·Priya SakthivelAnn Kari Lefvert
Apr 14, 2011·Journal of Clinical Immunology·Crisol Álvarez-QuirogaRoberto González-Amaro
Mar 23, 2013·Current Oncology Reports·Alexandra Drakaki, David F McDermott
Oct 1, 1995·Current Opinion in Immunology·J P AllisonD R Leach
Mar 17, 2004·Journal of Neuroimmunology·Paula S WaitsJulie D McLeod
May 3, 2005·Journal of Theoretical Biology·Jacob P Couturier, Robert S Root-Bernstein
Jul 31, 2013·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Takeshi HanagiriFumihiro Tanaka
Jul 5, 2003·The Journal of Surgical Research·Rebecca A SchroederPaul C Kuo
Mar 27, 2001·Transplantation Proceedings·M AlegreJ Bluestone
Feb 1, 1997·Transplantation Proceedings·H M GeorgiouA M Lew
Apr 1, 1997·Immunopharmacology·T M Petro, S Zhang
Sep 6, 2000·Veterinary Immunology and Immunopathology·I S ChoiE W Collisson
Mar 14, 2000·Veterinary Immunology and Immunopathology·I S ChoiE W Collisson
Jun 16, 2000·Journal of Neuroimmunology·M ParoliV Barnaba
Jul 17, 2003·Journal of Neuroimmunology·Tineke van VeenBernard M J Uitdehaag

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.